# Bernard Zinman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/bernard-zinman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 98,961 |
| Field | Diabetes Treatment and Management |
| h-index | 131 |
| i10-index | 551 |
| OpenAlex ID | https://openalex.org/A5090437675 |
| ORCID iD | 0000-0002-0041-1876 |
| Works | 946 |

## Researcher papers

Showing 12 of 33.

- [Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-cardiovascular-outcomes-and-mortality-in-type-2-diabetes/)
- [Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/liraglutide-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy/)
- [Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy](https://scholariq.org/papers/medical-management-of-hyperglycemia-in-type-2-diabetes-a-consensus-algorithm-for/)
- [Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-and-progression-of-kidney-disease-in-type-2-diabetes/)
- [Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy](https://scholariq.org/papers/glycemic-durability-of-rosiglitazone-metformin-or-glyburide-monotherapy/)
- [Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/effects-of-once-weekly-exenatide-on-cardiovascular-outcomes-in-type-2-diabetes/)
- [Impaired Fasting Glucose and Impaired Glucose Tolerance](https://scholariq.org/papers/impaired-fasting-glucose-and-impaired-glucose-tolerance/)
- [Liraglutide and Renal Outcomes in Type 2 Diabetes](https://scholariq.org/papers/liraglutide-and-renal-outcomes-in-type-2-diabetes/)
- [Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy](https://scholariq.org/papers/management-of-hyperglycemia-in-type-2-diabetes-a-consensus-algorithm-for-the/)
- [Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk](https://scholariq.org/papers/effect-of-linagliptin-vs-placebo-on-major-cardiovascular-events-in-adults-with/)
- [Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial](https://scholariq.org/papers/heart-failure-outcomes-with-empagliflozin-in-patients-with-type-2-diabetes-at/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.